Industry
Biotechnology
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Loading...
Open
19.26
Mkt cap
737M
Volume
228K
High
19.95
P/E Ratio
13.76
52-wk high
19.95
Low
18.92
Div yield
N/A
52-wk low
10.75
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 11:26 am
Portfolio Pulse from Benzinga Insights
April 11, 2024 | 8:31 pm
Portfolio Pulse from Avi Kapoor
March 22, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 10:38 am
Portfolio Pulse from Benzinga Insights
March 13, 2024 | 1:35 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 11:22 am
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 11:21 am
Portfolio Pulse from Benzinga Newsdesk
January 05, 2024 | 6:51 pm
Portfolio Pulse from Benzinga Newsdesk
January 05, 2024 | 12:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.